Moleculin Biotech shares surge 11.69% intraday after Annamycin shows no cardiotoxicity in five clinical trials.

Moleculin Biotech (NASDAQ: MBRX) surged 11.69% intraday following the announcement that its experimental anthracycline, Annamycin, demonstrated no cardiotoxicity in five clinical trials involving 90 subjects. The trials, conducted across the U.S. and EU, showed the drug’s safety even at doses exceeding the FDA’s lifetime maximum for traditional anthracyclines, with assessments validated by an independent expert affiliated with a leading cancer research institute. The data highlights Annamycin’s potential as a non-cardiotoxic alternative for treating acute myeloid leukemia and soft tissue sarcoma, addressing a significant unmet medical need. The positive safety profile, coupled with early efficacy signals, bolstered investor confidence in the drug’s development prospects, driving the sharp intraday rally.